Enzo Biochem, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

ENZ 4.65
price chart
Enzo Biochem (ENZ) in Focus: Stock Moves 6.9% Higher - Tale of the Tape
Enzo Biochem Inc. ( ENZ ) was a big mover last session with its shares rising nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.
Related articles »  
Enzo Biochem Inc. (ENZ) Drops 6.89% on November 20
Enzo Biochem Inc. (ENZ) was one of the Russell 2000's biggest losers for November 20 as the stock slid 6.89% to $4.19, a loss of $0.31 per share.
Related articles »  
Enzo Biochem, Inc. v. Applera Corp. (Fed. Cir. 2010)
Enzo The '824, '767, '928, and '830 patents, which are owned by Plaintiffs-Appellants Enzo Biochem, Inc., Enzo Life Sciences, Inc., and Yale University ("Enzo"), are directed to various techniques for labeling and detecting nucleic acids. More ...
What Falling Estimates amp; Price Mean for Enzo Biochem (ENZ)
One such stock that you may want to consider dropping is Enzo Biochem Inc. (ENZ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
Related articles »  
Could Enzo Biochem's Intellectual Property Lawsuits Be Worth Billions?
Enzo Biochem, Inc. (NYSE:ENZ) is an integrated life sciences and biotechnology company divided into three segments: Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics.
Enzo Biochem Reports Across the Board Second Quarter 2014 Improved Results
�Enzo Biochem's second fiscal quarter displayed strong resiliency and growth,� said Barry Weiner, President. �The overall improvement was achieved despite the continuing challenges in healthcare, the cross winds in the regulatory sector that continue ...
Related articles »  
Enzo Biochem (ENZ) Q3 2014 Results - Earnings Call Transcript (ENZ)
Good morning, and welcome to the Enzo Biochem, Inc. Third Quarter 2014 Operating Results Conference Call. I will now read the company's Safe Harbor statement.
Enzo Biochem Reports Strong Third Fiscal Quarter Results  Business Wire (press release)
Related articles »  
Enzo Biochem Announces Appointment of James M. O'Brien as Senior VP ...
Jim has held leadership positions in the areas of planning and strategic development, financial analysis, SEC reporting and internal controls for both large and small multi-national public companies,� said Barry Weiner, President of Enzo Biochem, Inc ...
Healthcare Stocks Little Changed; Enzo Biochem, Innate Pharma Partnering on ...  NASDAQ
Enzo Biochem Unit Partners with Innate Pharma S.A. to Validate Key System ...  MarketWatch
Related articles »  
Enzo Biochem Awarded US Patent on More Efficient Vector for Use in Gene ...
NEW YORK--(BUSINESS WIRE)--Enzo Biochem Inc. (NYE:ENZ) announced that it has been assigned U.S. Patent Office Patent No. 8,742,090, related to the construct of an artificial vector capable of greater efficiency, in general, in targeting specific cells ...
Related articles »  
Earnings Estimates Moving Higher for Enzo Biochem - ENZ Time to Buy?
Enzo Biochem Inc. (ENZ) is an integrated life sciences and biotechnology firm that could be an interesting play for investors.
Related articles »